Clinical Trials Directory

Trials / Unknown

UnknownNCT05486871

Oncological and Functional Outcomes of Laparoscopic Partial Nephrectomy in Renal Cell Carcinoma Stages T1 Versus T2a: Prospective Comparative Study.

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
30 (estimated)
Sponsor
Sohag University · Academic / Other
Sex
Male
Age
Healthy volunteers
Not accepted

Summary

RCC represents around 3% of all cancers, with the highest incidence occurring in Western countries . Within the several RCC risk factors identified, smoking, obesity, and hypertension are most strongly associated with RCC . The EUA guidelines recommend PN for patients with T1 tumors, as PN preserved kidney function better after surgery, thereby potentially lowering the risk of development of cardiovascular disorders as well as improving overall survival(OS) for PN compared to RN, there is very limited evidence on the optimal surgical treatment for patients with larger renal masses (T2) . Currently, the upper limit of PN indications remains undefined and is determined by an individual surgeon's expertise and preference. The degree of variability in the choice between PN and RN for a given tumor increases with tumor size. Surgeons committed to nephron-sparing are likely to expand the indications of PN, while those concerned with increased morbidity and doubtful of the clinical relevance of a moderate decrease in renal function are likely to perform RN, regardless of tumor size .

Conditions

Interventions

TypeNameDescription
PROCEDURElaparoscopic partial nephrectomyThis is a prospective non- randomized controlled study of patients with RCC Who will be referred to urology department, Sohag university hospital. Our comparative study contained two groups according to tumor stage at preoperative contrast study: Group \[A\] : 15 patients with T1 RCC (≤ 7 cm). Group \[B\] : 15 patients with T2a RCC (≤ 10 cm). the patients will be subjected to laparoscopic partial nephrectomy then will be followed up for two years for oncological and functional outcomes.

Timeline

Start date
2022-08-20
Primary completion
2024-08-20
Completion
2024-08-20
First posted
2022-08-04
Last updated
2022-08-04

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT05486871. Inclusion in this directory is not an endorsement.